Sugi Predict

Sugi Predict / Targets / ERG

ERG

Transcriptional regulator ERG · P11308 · ERG on Sugi Atlas →

2,453 patent compounds predicted against ERG, 1,781 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8195337 SCHEMBL8195337 0.32 5/20
SCHEMBL8098513 SCHEMBL8098513 0.50 4/20
SCHEMBL8437320 SCHEMBL8437320 0.50 4/20
SCHEMBL4147076 SCHEMBL4147076 0.44 4/20
SCHEMBL14850784 SCHEMBL14850784 1.00 3/20
SCHEMBL16049477 SCHEMBL16049477 1.00 3/20
SCHEMBL14850765 SCHEMBL14850765 0.81 3/20
SCHEMBL16048688 SCHEMBL16048688 0.81 3/20
SCHEMBL2563421 SCHEMBL2563421 0.79 3/20
SCHEMBL14850721 SCHEMBL14850721 0.79 3/20
SCHEMBL14850804 SCHEMBL14850804 0.75 3/20
SCHEMBL16048096 SCHEMBL16048096 0.75 3/20
SCHEMBL14850829 SCHEMBL14850829 0.72 3/20
SCHEMBL16048144 SCHEMBL16048144 0.72 3/20
SCHEMBL14850720 SCHEMBL14850720 0.71 3/20
SCHEMBL16049365 SCHEMBL16049365 0.71 3/20
SCHEMBL14850762 SCHEMBL14850762 0.70 3/20
SCHEMBL16049384 SCHEMBL16049384 0.70 3/20
SCHEMBL16049386 SCHEMBL16049386 0.70 3/20
SCHEMBL14850724 SCHEMBL14850724 0.69 3/20

Clinical trials — most relevant to ERG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients PHASE2/PHASE3RECRUITING
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study PHASE3ACTIVE_NOT_RECRUITING
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer PHASE2COMPLETED
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) PHASE2COMPLETED
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer PHASE2COMPLETED
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma PHASE2COMPLETED
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma PHASE2COMPLETED
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer PHASE2COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 PHASE2COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
Utilizing A Genomic Sig for BRCAness to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca PHASE2COMPLETED
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies PHASE1RECRUITING
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features nanUNKNOWN
The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy nanRECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. nanUNKNOWN
Fungal Infections in Patients With Hematological Malignancies nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma nanUNKNOWN
Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer nanNOT_YET_RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
A Pilot Study on ALK Gene Mutations in Neuroblastoma nanUNKNOWN
Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1 nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ERG binder may also engage these)

ProteinNameSimilarity
P81270 — 1.000 P81270 →
Q90837 — 1.000 Q90837 →
Q29RS8 — 1.000 Q29RS8 →
P41157 — 1.000 P41157 →
FLI1 Friend leukemia integration 1 transcription factor 1.000 landscape →
P26323 — 1.000 P26323 →
P97360 — 0.993 P97360 →
ETV1 ETS translocation variant 1 0.993 landscape →
Q91904 — 0.992 Q91904 →
PAX2 Paired box protein Pax-2 0.992 landscape →
P24610 — 0.992 P24610 →
Q62661 — 0.992 Q62661 →
ETV6 Transcription factor ETV6 0.992 landscape →
Q9PVY9 — 0.992 Q9PVY9 →
Q5R7I3 — 0.992 Q5R7I3 →
P01105 — 0.991 P01105 →
P10157 — 0.991 P10157 →
Q1KKW8 — 0.991 Q1KKW8 →
P32114 — 0.991 P32114 →
Q9CXC9 — 0.991 Q9CXC9 →
Q7Z353 — 0.991 Q7Z353 →
B0FZP1 — 0.991 B0FZP1 →
Q0VC65 — 0.991 Q0VC65 →
Q1KL10 — 0.991 Q1KL10 →
PAX8 Paired box protein Pax-8 0.990 landscape →
P41164 — 0.990 P41164 →
Q2KJ34 — 0.990 Q2KJ34 →
P41935 — 0.990 P41935 →
Q9XSK8 — 0.990 Q9XSK8 →
Q80WT2 — 0.990 Q80WT2 →